Prospective Multicentric Evaluation of a Bladder Preservation Strategy Using a Combination of Neoadjuvant Chemotherapy and Optimal Bladder Transurethral Resection in Patients With a Urothelial Carcinoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cisplatin; Doxorubicin; Granulocyte colony-stimulating factors; Methotrexate; Vinblastine
- Indications Urogenital cancer
- Focus Therapeutic Use
- Acronyms ReChiVe
- 04 Dec 2020 Biomarkers information updated
- 28 Jun 2012 Planned number of patients changed from 77 to 90 as reported by European Clinical Trials Database.
- 24 Apr 2012 Planned End Date changed from 1 Dec 2017 to 1 Dec 2020 as reported by ClinicalTrials.gov.